Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 12/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721576 | 0.99 | TFPI (0.61) | TFPIOPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL29525489 | 0.95 | TFPI (0.63) | TFPIOPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL29376413 | 0.94 | TFPI (0.56) | TFPIOPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL29376362 | 0.93 | TFPI (0.66) | TFPI | |
| SCHEMBL30861917 | 0.93 | TFPI (0.61) | TFPIOPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL31614449 | 0.92 | OPRD1 (0.53) | TFPIOPRM1OPRD1OPRK1NPY1R | |
| SCHEMBL34468124 | 0.92 | TFPI (0.60) | TFPIOPRM1OPRD1OPRK1NPBWR1 | |
| SCHEMBL29373287 | 0.91 | TFPI (0.66) | TFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL31614444 | 0.91 | OPRD1 (0.56) | TFPIOPRM1OPRD1OPRK1NPY1R | |
| SCHEMBL31614415 | 0.91 | OPRD1 (0.55) | TFPIOPRM1OPRD1OPRK1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060201-A | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-111819191-B | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-08-20 | — | — | CN | claimed |
| EP-3704143-B1 | CHEMO-ENZYMATIC SYNTHESIS OF LIRAGLUTIDE, SEMAGLUTIDE AND GLP-1 | FRESENIUS KABI IPSUM S R L (IT) | 2023-10-18 | — | — | EP | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| CN-119060201-A | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4291647-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi iPSUM S.r.l. (IT) | 2023-12-20 | — | — | EP | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3704143-B1 | CHEMO-ENZYMATIC SYNTHESIS OF LIRAGLUTIDE, SEMAGLUTIDE AND GLP-1 | FRESENIUS KABI IPSUM S R L (IT) | 2023-10-18 | — | — | EP | disclosed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022171667-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-08-18 | — | — | WO | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | TFPI 1087/4885OPRM1 2309/4885OPRD1 3623/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | TFPI 525/4885OPRM1 4009/4885OPRD1 3405/4885 |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | TFPI 3297/4885OPRM1 2254/4885OPRD1 1916/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | TFPI 525/4885OPRM1 4009/4885OPRD1 3405/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | TFPI 2018/4885OPRM1 490/4885OPRD1 408/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | TFPI 874/4885OPRM1 4237/4885OPRD1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.